Status:
COMPLETED
Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid
Lead Sponsor:
Zhi-Hong Liu, M.D.
Conditions:
Idiopathic Membranous Nephropathy
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The purpose of this study is: To explore the potential role of Tripterygium wilfordii plus steroid in the treatment of membranous nephropathy. To investigate the safety and tolerability of Tripterygi...
Detailed Description
Idiopathic membranous nephropathy is the most common cause of nephrotic syndrome in adults. Over the past decade, a number of studies have reported therapeutic efficacy for treatment with tacrolimus p...
Eligibility Criteria
Inclusion
- Biopsy-proven idiopathic membranous nephropathy
- Nephrotic syndrome with proteinuria ( \> 3.5 g/day) and serum albumin \< 30 g/dl
- Age 18-65 years with informed consent
Exclusion
- Patient with elevated serum creatinine concentration
- Prior therapy with sirolimus, CSA, MMF, or azathioprin, cytoxan, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days
- Active/serious infection
- Patient with hepatitis B surface antigen or who is hepatitis C antibody positive
- Patient who is diabetic
- Patient is allergic or intolerant to macrolide antibiotics or tacrolimus
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2013
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01161459
Start Date
June 1 2010
End Date
October 1 2013
Last Update
June 2 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine
Nanjing, Jiangsu, China, 210002